Ipca Labs: revenue up 14%, margins wider, FY27 guidance kept despite costs
Ipca Laboratories reported 14% revenue growth and a 22.97% consolidated EBITDA margin for Q2 FY27, leaving its full-year guidance unchanged.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Indian drugmaker Ipca Laboratories (IPCALAB) posted second-quarter FY27 revenue up 14%, while its consolidated EBITDA margin climbed to 22.97%. Domestic and export formulations both performed strongly.
The company kept its FY27 outlook in place, still targeting 14%-16% revenue growth and a 22%-23% margin, even though freight, input and energy costs remain elevated.
why it matters
The result shows revenue growth and profitability moving together, which is hard in a market with expensive logistics and energy. Holding guidance unchanged suggests management sees current cost pressure as still within its plan. For investors in Indian pharma, the report points to steady margins despite costly resources.
market impact
IPCA shares: strong quarter supports the stock, higher freight and energy costs weigh on it
- Ipca Laboratories shares mixed — strong revenue and margins offset by higher freight and energy costs
tags
instruments
sources
- IPCALAB: Revenue grew 14% and EBITDA margin expanded, while FY27 guidance held amid cost pressures — TradingView, 5 November 2026 at 12:51 UTC
- IPCALAB: Revenue rose 14%, margins expanded, and FY27 guidance was maintained amid cost pressures — TradingView, 5 November 2026 at 12:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗